We recently published our article 5 Stocks That Beat Wall Street at Its Own Game in Q2 2026. To read the full story, you can go directly to 10 Stocks That Beat Wall Street at Its Own Game in Q2 2026. In this article, we discuss MeiraGTx Holdings plc (NASDAQ:MGTX) as one of the stocks gaining attention, and here’s a closer look at why it stands out in today’s market.
There is an old lesson on Wall Street that investors learn quickly: a company does not necessarily need to post spectacular earnings to impress the market. Sometimes, it simply needs to perform better than analysts expected.
That is what makes earnings season so fascinating.
Every quarter, publicly traded companies open their books and reveal how much money they made, how quickly revenue grew, whether costs increased or declined, and what management expects in the months ahead. Analysts spend weeks building forecasts before those reports arrive, estimating everything from revenue and profit margins to one of the market’s most closely watched numbers: earnings per share, or EPS.
And then reality gets its turn.
Sometimes analysts get remarkably close. Other times, companies produce earnings results that leave Wall Street scrambling to revise its assumptions.
For investors following the latest stock market news, quarterly earnings reports, earnings surprise stocks, companies beating analyst estimates, NASDAQ stocks to watch and NYSE stocks to watch, those differences can be extremely important.
An EPS beat occurs when a company reports earnings per share above the consensus estimate established by Wall Street analysts. For example, if analysts expect a company to earn $0.30 per share and it reports $0.45, the company has delivered a $0.15 positive earnings surprise.
The arithmetic is simple. The implications can be much more complicated.
One interesting piece of Wall Street trivia is that companies can report rising profits and still see their shares fall. On the other hand, a company can post relatively modest earnings and watch investors become more optimistic simply because the result was better than expected.
That happens because the stock market is largely an expectations game.
Share prices do not reflect only what a company is earning today. They also attempt to price in what investors believe that company could earn tomorrow, next quarter and several years into the future. When actual results suddenly come in much stronger than forecasts, those expectations may have to be adjusted.
This is also why even a difference of several cents per share can matter.
For a company with millions of shares outstanding, a seemingly small EPS difference can represent millions of dollars in profitability compared with what analysts had projected. More importantly, a strong earnings beat may suggest that Wall Street underestimated something happening inside the business.
Perhaps customer demand was stronger than expected. Maybe management reduced costs faster than analysts predicted. Profit margins could have improved. A new product might have performed better than anticipated. Revenue growth may have accelerated, or management may simply have executed more effectively than the market had assumed.
That uncertainty is exactly what makes earnings season one of the most closely followed periods on Wall Street.
When Beating Expectations Becomes the Bigger Story
Not all earnings surprises are created equal.
A company beating analyst estimates by one or two cents is technically an earnings beat, but it does not carry the same weight as a company exceeding expectations by $0.20, $0.50 or even more than $1 per share.
The situation becomes even more interesting when analysts are expecting a loss and the company reports a profit instead.
That is one of the more dramatic reversals that can occur during quarterly earnings season.
Suppose Wall Street expects a company to lose $0.40 per share. Instead, the business reports positive EPS. Suddenly, the conversation surrounding the stock can change. Investors may begin wondering whether profitability is arriving earlier than anticipated, whether business conditions have improved or whether previous analyst forecasts were simply too pessimistic.
For smaller companies, growth stocks, turnaround plays and emerging businesses, that type of surprise can put a stock on investors’ radar almost overnight.
There is another interesting Wall Street reality at work here.
Some of the world’s largest companies are followed by dozens of analysts, making their consensus estimates relatively broad. Smaller publicly traded companies may have considerably fewer analysts covering them. With fewer estimates contributing to the consensus, the forecasts can occasionally leave more room for unexpected results.
That helps explain why some of the most eye-catching EPS surprises can come from companies that receive far less mainstream financial coverage.
Of course, investors should never assume that an earnings beat automatically makes a stock a good investment.
A company could beat EPS expectations because of temporary cost reductions, tax benefits, accounting adjustments or other factors that may not continue. Revenue could still disappoint. Management could provide weaker guidance. Debt could remain elevated, cash flow might be poor or the stock could already trade at an expensive valuation.
That is why professional investors usually look beyond the headline number.
They examine revenue growth, operating margins, free cash flow, balance-sheet strength, forward guidance, valuation and the sustainability of earnings. EPS is an important starting point, but it is rarely the entire story.
Still, a substantial earnings surprise deserves attention because it tells investors one important thing immediately: Wall Street underestimated the company’s performance.
And sometimes, Wall Street underestimated it by a lot.
Another piece of market trivia is that a stock does not always rally after beating earnings estimates. A company can report excellent numbers and still decline if investors were expecting an even stronger result or if the stock had already climbed significantly before earnings.
This phenomenon is often described as expectations being “priced in.”
For example, if investors aggressively buy a stock ahead of earnings because they anticipate a strong report, the eventual earnings beat might not be enough to push shares higher. Traders could instead take profits, particularly if management provides cautious guidance for the following quarter.
That is why investors often say markets are forward-looking.
Yesterday’s earnings matter, but tomorrow’s expectations usually matter more.
Yet earnings surprises can still provide valuable clues about companies whose operating performance may be improving faster than analysts anticipated.
For investors searching for stocks beating earnings estimates, strong quarterly earnings, top earnings surprise stocks, companies outperforming Wall Street expectations, small-cap stocks to watch, growth stocks, NASDAQ earnings results and NYSE earnings results, the latest round of reports offers several noteworthy examples.
The companies in this ranking come from very different corners of the market, but they share one important characteristic: each delivered earnings per share above analysts’ expectations.
Some exceeded forecasts by only a few cents.
Others produced significantly larger surprises.
And at the top of the ranking are the kinds of results that can make even experienced market watchers take a second look.
The following 10 stocks are ranked according to the size of their positive EPS surprise, moving from the more modest beats to the company that delivered the biggest earnings shock of the group.
CHECK THIS OUT: 10 Stocks With Billion-Dollar Potential You Should Not Miss and10 Stocks Under $10 Analysts Believe Could Soar 200%.
Our Methodology
To arrive with our list of the 10 stocks that beat wall street at its own game in Q2 2026, we ranked the stocks based on the size of their positive Q2 EPS surprise versus Wall Street consensus estimates, with the biggest earnings beat taking the No. 1 spot.
5 Stocks That Beat Wall Street at Its Own Game in Q2 2026
1. MeiraGTx Holdings plc (NASDAQ:MGTX)
MeiraGTx Holdings plc (NASDAQ: MGTX) takes the No. 1 spot, and there was not much competition when the earnings surprise was measured in absolute dollars per share.
MeiraGTx Holdings plc (NASDAQ: MGTX) reported diluted EPS of $1.71 for the second quarter. Using the analyst consensus underlying this ranking, Wall Street had been expecting a loss of $0.44 per share, creating a massive $2.15 positive EPS surprise. Other market-data providers showed slightly different pre-report loss estimates, but all told the same basic story: analysts expected MeiraGTx Holdings plc (NASDAQ: MGTX) to lose money, and instead it reported a very large quarterly profit. Shares were around $13.52 in the ranking snapshot, up 6.67%.
The magnitude of the turnaround becomes clearer when looking beyond EPS.
MeiraGTx Holdings plc (NASDAQ: MGTX) reported second-quarter revenue of approximately $321.4 million, compared with just $3.7 million a year earlier. Net income attributable to ordinary shareholders reached $160.7 million, compared with a $38.8 million loss in the year-ago quarter. Basic EPS was $1.76 and diluted EPS was $1.71.
At first glance, that looks like the kind of commercial breakthrough biotechnology investors dream about. But this is where the details matter.
The enormous revenue increase did not come from hundreds of millions of dollars in newly launched drug sales. A substantial portion reflected licensing, collaboration and service revenue. MeiraGTx Holdings plc (NASDAQ: MGTX) recognized $204.6 million of related-party license revenue associated with licenses granted for certain programs, another $104.9 million of related-party service revenue, and $11.9 million of service revenue connected partly with manufacturing services provided under a collaboration with Eli Lilly.
That distinction is critical for investors evaluating the sustainability of the headline EPS number. Licensing and collaboration payments can create very large quarterly profits but may not recur at the same level every three months. The No. 1 ranking therefore reflects the magnitude of the earnings surprise, not a claim that $1.71 in quarterly EPS represents a new normal earnings run rate.
Still, the quarter was significant for reasons extending beyond accounting recognition.
MeiraGTx Holdings plc (NASDAQ: MGTX) is a clinical-stage genetic medicines company developing therapies across inherited retinal diseases, radiation-induced xerostomia, Parkinson’s disease and other conditions. During the quarter, the company acquired full rights to botaretigene sparoparvovec, commonly called bota-vec, from Johnson & Johnson and continued preparing for regulatory filings. It also received FDA Breakthrough Therapy Designation for AAV2-hAQP1, an experimental treatment targeting radiation-induced xerostomia.
The balance sheet improved significantly as well. Cash, cash equivalents and restricted cash stood at approximately $145.4 million at the end of June compared with $34.4 million a year earlier. MeiraGTx Holdings plc (NASDAQ: MGTX) also entered an agreement with Oberland Capital providing access to as much as $400 million in strategic investment, including substantial non-dilutive capital.
At the same time, research and development spending increased to $57.8 million from $33.5 million, reflecting the cost of pushing multiple genetic medicine programs forward and reacquiring rights to bota-vec. That is another reminder that biotechnology companies can have unusually volatile income statements as licensing deals, research spending, milestones and clinical-development investments move from quarter to quarter.
That volatility is precisely what made this earnings report such an outlier.
Wall Street went into the quarter expecting another loss from a clinical-stage biotechnology company. Instead, MeiraGTx Holdings plc (NASDAQ: MGTX) delivered more than $300 million in revenue, $160 million in quarterly net income and $1.71 in diluted EPS.
For investors searching for biotech stocks beating earnings estimates, gene therapy stocks, NASDAQ stocks to watch, biggest EPS surprises, Q2 earnings winners and stocks that crushed Wall Street expectations, MeiraGTx Holdings plc (NASDAQ: MGTX) produced the most dramatic earnings surprise in this ranking.
It was not merely an earnings beat. It was the kind of result that demonstrates why earnings season can still catch Wall Street completely off guard.
YOU MUST READ THIS: Amazon (AMZN) and Alphabet (GOOGL) Just Made Jim Cramer’s Top 10 – Part 2
Disclosure: No material interests to disclose. This article was originally published on Global Market Bulletin.
